Dr. Reddy’s Laboratories Ltd $RDY Shares Sold by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC reduced its position in shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDY) by 66.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 49,017 shares of the company’s stock after selling 96,860 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Dr. Reddy’s Laboratories were worth $685,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in RDY. Westside Investment Management Inc. acquired a new position in Dr. Reddy’s Laboratories during the 2nd quarter worth approximately $35,000. EverSource Wealth Advisors LLC grew its holdings in Dr. Reddy’s Laboratories by 71.7% during the second quarter. EverSource Wealth Advisors LLC now owns 3,100 shares of the company’s stock worth $47,000 after acquiring an additional 1,294 shares during the period. Farther Finance Advisors LLC raised its position in Dr. Reddy’s Laboratories by 217.4% in the third quarter. Farther Finance Advisors LLC now owns 3,568 shares of the company’s stock worth $50,000 after acquiring an additional 2,444 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Dr. Reddy’s Laboratories in the second quarter worth $67,000. Finally, Allworth Financial LP lifted its holdings in Dr. Reddy’s Laboratories by 37.8% in the second quarter. Allworth Financial LP now owns 4,827 shares of the company’s stock valued at $73,000 after acquiring an additional 1,323 shares during the period. Hedge funds and other institutional investors own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Trading Up 0.1%

Shares of RDY stock opened at $12.93 on Wednesday. Dr. Reddy’s Laboratories Ltd has a fifty-two week low of $12.26 and a fifty-two week high of $16.17. The stock has a market cap of $10.80 billion, a P/E ratio of 15.97, a P/E/G ratio of 6.36 and a beta of 0.37. The business has a fifty day simple moving average of $13.85 and a 200-day simple moving average of $14.11. The company has a quick ratio of 1.35, a current ratio of 1.85 and a debt-to-equity ratio of 0.03.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings data on Friday, October 24th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.18 by $0.01. The business had revenue of $993.72 million for the quarter, compared to analyst estimates of $944.26 million. Dr. Reddy’s Laboratories had a net margin of 17.14% and a return on equity of 17.13%. On average, analysts forecast that Dr. Reddy’s Laboratories Ltd will post 0.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Dr. Reddy’s Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Dr. Reddy’s Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $16.90.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.